Lead product VSN16R to begin Phase II trials

VSN16R a novel orally active small molecule compound that is substantially better tolerated than existing anti-spastic agents. VSN16R does not cause the flaccidity, sedation or other cognitive side-effects that are major disadvantages of other available drugs.

VSN16R has completed its Phase I clinical trial and has demonstrated excellent safety and tolerability. This first in man study of VSN16R enrolled a total of 80 healthy volunteers in a double blind, placebo-controlled, single ascending dose and multiple ascending dose design and food effect study. The study was carried out by Quintiles, the world's leading clinical research organisation.

VSN16R acts through a proprietary mode of action that is not currently disclosed. The mode of action of the VSN compounds opens up many other potential therapeutic uses beyond spasticity. These new indications are currently under investigation